Sino-American biotech MicuRx Pharmaceuticals has raised $55 million to fund a pair of late-phase trials of its antibiotic.
Regeneron and Sanofi have snagged a priority review for their potential blockbuster atopic dermatitis drug, dupilumab.
With its measurable impact on patient survival, there’s no denying that immunotherapy is already causing momentum in ways that cancer is treated. Learn more…
Mologen is seeking to raise €16 million to fund a suite of trials of its TLR9 agonist in patients with colorectal cancer, small cell lung cancer and HIV.
Intrexon has done deals with two of the portfolio companies from a fund dedicated to promoting the use of the synthetic biology player's tech: Genten…
Neuroderm has reported that Parkinson’s patients who have used its minipump levodopa and carbidopa delivery system have done so effectively.
Israeli biotech BioLineRx was up about 25% in early trading on news that it has done a second in-licensing deal for a nonalcoholic steatohepatitis (NASH)…
GSK's new CEO, LabCorp's Covance leadership change and more.
Lundbeck has chalked up another Phase III failure for the Alzheimer's field. Neither dose hit the primary endpoint or showed separation from placebo.
AC Immune is offloading 6 million IPO shares, 32% more than originally planned, at the bottom end of its targeted $11 to $13 price range.
Daniel Soland has quit as CEO of uniQure "due to personal family reasons" 9 months after taking the job.